UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Imaging for local recurrence of breast cancer

Journal of cancer research and clinical oncology, 2024-04, Vol.150 (4), p.200-200, Article 200

2024

Volltextzugriff (PDF)

Real-world effectiveness of ribociclib + aromatase inhibitor, or endocrine monotherapy, or chemotherapy as first-line treatment in postmenopausal women with HR-positive, HER2-negative locally advanced or metastatic breast cancer: The RIBANNA study

Annals of oncology, 2018-10, Vol.29, p.viii89-viii89

2018

Volltextzugriff (PDF)

“Pregnant and Operating”: Evaluation of a Germany-wide Survey Among Female Gynaecologists and Surgeons

Geburtshilfe und Frauenheilkunde, 2014-09, Vol.74 (9), p.875-880

2014

Volltextzugriff (PDF)

P–350 Utilizing indocyanine green (ICG)-enhanced fluorescence to localize the ureter during robotic surgery for DIE and a concomitant crossed renal ectopia

Human reproduction (Oxford), 2021-08, Vol.36 (Supplement_1)

2021

Volltextzugriff (PDF)

374P Real-world (Rw) outcomes in patients (pts) with hormone receptor-positive and human epidermal growth factor receptor-2 negative (HR+/HER2-) metastatic breast cancer (mBC) treated with chemotherapy (CT) in France and Germany

Annals of oncology, 2024-09, Vol.35, p.S375-S376

2024

Volltextzugriff (PDF)

409P Treatment of elderly patients (pts; > 75 years) with 1st-line ribociclib (RIB) + endocrine therapy (ET) or endocrine monotherapy in clinical routine: Real-world data from the RIBANNA study (5th interim analysis (IA))

Annals of oncology, 2023-10, Vol.34, p.S354-S355

2023

Volltextzugriff (PDF)

441P Real-world efficacy of ribociclib (RIB) + aromatase inhibitor (AI)/fulvestrant (FUL) in subgroups of special interest: 5th interim analysis (IA) of the RIBANNA study

Annals of oncology, 2023-10, Vol.34, p.S366-S367

2023

Volltextzugriff (PDF)

411P Therapy management and safety of 1st-line ribociclib (RIB) + aromatase inhibitor (AI)/fulvestrant (FUL) in clinical routine: Real-world data from the RIBANNA study (5th interim analysis (IA))

Annals of oncology, 2023-10, Vol.34, p.S355-S356

2023

Volltextzugriff (PDF)

Comparing the outcome between multicentric and multifocal breast cancer: what is the impact on survival, and is there a role for guideline-adherent adjuvant therapy? A retrospective multicenter cohort study of 8,935 patients

Breast cancer research and treatment, 2013-12, Vol.142 (3), p.579-590

2013

Volltextzugriff (PDF)

Liberal transfusion strategy to prevent mortality and anaemia-associated, ischaemic events in elderly non-cardiac surgical patients - the study design of the LIBERAL-Trial

Trials, 2019-02, Vol.20 (1), p.101-101, Article 101

2019

Volltextzugriff (PDF)

Treatment and outcome in metastatic lobular breast cancer in the prospective German research platform OPAL

Breast cancer research and treatment, 2023-04, Vol.198 (3), p.545-553

2023

Volltextzugriff (PDF)

Financial difficulties in breast cancer survivors with and without migration background in Germany—results from the prospective multicentre cohort study BRENDA II

Supportive care in cancer, 2022-08, Vol.30 (8), p.6677-6688

2022

Volltextzugriff (PDF)

Adjuvant bisphosphonates or RANK-ligand inhibitors for patients with breast cancer and bone metastases: A systematic review and network meta-analysis

Critical reviews in oncology/hematology, 2019-05, Vol.137, p.1-8

2019

Volltextzugriff (PDF)

282TiPReal-world effectiveness of ribociclib + aromatase inhibitor, or endocrine monotherapy, or chemotherapy as first-line treatment in postmenopausal women with HR-positive, HER2-negative locally advanced or metastatic breast cancer: The RIBANNA study

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

The impact of adjuvant radiotherapy on the survival of primary breast cancer patients: a retrospective multicenter cohort study of 8935 subjects

Annals of oncology, 2014-03, Vol.25 (3), p.628-632

2014

Volltextzugriff (PDF)

Case reports of genital tract tumours in cows

Veterinární medicína, 2020-01, Vol.65 (9), p.401-408

2020

Volltextzugriff (PDF)

Standard treatment of female patients with breast cancer decreases substantially for women aged 70 years and older: a German clinical cohort study

Annals of oncology, 2010-04, Vol.21 (4), p.748-753

2010

Volltextzugriff (PDF)

Triple-negative breast cancer: the impact of guideline-adherent adjuvant treatment on survival—a retrospective multi-centre cohort study

Breast cancer research and treatment, 2012-04, Vol.132 (3), p.1073-1080

2012

Volltextzugriff (PDF)

258P Real-world (rw) outcomes in patients (pts) with hormone receptor-positive and human epidermal growth factor receptor-2-negative (HR+/HER2-) metastatic breast cancer (mBC) treated with chemotherapy (CT) in France

ESMO open, 2024-05, Vol.9, p.103279, Article 103279

2024

Volltextzugriff (PDF)

To which extent do breast cancer survivors feel well informed about disease and treatment 5 years after diagnosis?

Breast cancer research and treatment, 2021-02, Vol.185 (3), p.677-684

2021

Volltextzugriff (PDF)

Endocrine therapy in obese patients with primary breast cancer: another piece of evidence in an unfinished puzzle

Breast cancer research and treatment, 2012-02, Vol.131 (3), p.925-931

2012

Volltextzugriff (PDF)

216P What is driving treatment decision following 1st line ribociclib (RIB) + aromatase inhibitor (AI)/fulvestrant (FUL) in clinical routine? Real-world data from the RIBANNA study (6th interim analysis (IA))

ESMO open, 2024-05, Vol.9, p.103238, Article 103238

2024

Volltextzugriff (PDF)

German National Consensus Recommendations on Nutrition and Lifestyle in Pregnancy by the ‘Healthy Start – Young Family Network’

Annals of nutrition and metabolism, 2013-01, Vol.63 (4), p.311-322

2013

Volltextzugriff (PDF)

Positive Effect of HPA Lanolin versus Expressed Breastmilk on Painful and Damaged Nipples during Lactation

Skin pharmacology and physiology, 2011-01, Vol.24 (1), p.27-35

2011

Volltextzugriff (PDF)

A comparison of international breast cancer guidelines – Do the national guidelines differ in treatment recommendations?

European journal of cancer (1990), 2012-01, Vol.48 (1), p.1-11

2012

Volltextzugriff (PDF)

1 – 25 von 525

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(421)
Mit Volltextzugriff
(393)

Publikationsform

Sprache

Englisch
(301)
Deutsch
(227)
Französisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(7)

Menü

Weitere Dienste

Einstellungen

Imaging for local recurrence of breast cancer

Real-world effectiveness of ribociclib + aromatase inhibitor, or endocrine monotherapy, or chemotherapy as first-line treatment in postmenopausal women with HR-positive, HER2-negative locally advanced or metastatic breast cancer: The RIBANNA study

“Pregnant and Operating”: Evaluation of a Germany-wide Survey Among Female Gynaecologists and Surgeons

P–350 Utilizing indocyanine green (ICG)-enhanced fluorescence to localize the ureter during robotic surgery for DIE and a concomitant crossed renal ectopia

374P Real-world (Rw) outcomes in patients (pts) with hormone receptor-positive and human epidermal growth factor receptor-2 negative (HR+/HER2-) metastatic breast cancer (mBC) treated with chemotherapy (CT) in France and Germany

409P Treatment of elderly patients (pts; > 75 years) with 1st-line ribociclib (RIB) + endocrine therapy (ET) or endocrine monotherapy in clinical routine: Real-world data from the RIBANNA study (5th interim analysis (IA))

441P Real-world efficacy of ribociclib (RIB) + aromatase inhibitor (AI)/fulvestrant (FUL) in subgroups of special interest: 5th interim analysis (IA) of the RIBANNA study

411P Therapy management and safety of 1st-line ribociclib (RIB) + aromatase inhibitor (AI)/fulvestrant (FUL) in clinical routine: Real-world data from the RIBANNA study (5th interim analysis (IA))

Comparing the outcome between multicentric and multifocal breast cancer: what is the impact on survival, and is there a role for guideline-adherent adjuvant therapy? A retrospective multicenter cohort study of 8,935 patients

Liberal transfusion strategy to prevent mortality and anaemia-associated, ischaemic events in elderly non-cardiac surgical patients - the study design of the LIBERAL-Trial

Treatment and outcome in metastatic lobular breast cancer in the prospective German research platform OPAL

Financial difficulties in breast cancer survivors with and without migration background in Germany—results from the prospective multicentre cohort study BRENDA II

Adjuvant bisphosphonates or RANK-ligand inhibitors for patients with breast cancer and bone metastases: A systematic review and network meta-analysis

282TiPReal-world effectiveness of ribociclib + aromatase inhibitor, or endocrine monotherapy, or chemotherapy as first-line treatment in postmenopausal women with HR-positive, HER2-negative locally advanced or metastatic breast cancer: The RIBANNA study

The impact of adjuvant radiotherapy on the survival of primary breast cancer patients: a retrospective multicenter cohort study of 8935 subjects

Case reports of genital tract tumours in cows

Standard treatment of female patients with breast cancer decreases substantially for women aged 70 years and older: a German clinical cohort study

Triple-negative breast cancer: the impact of guideline-adherent adjuvant treatment on survival—a retrospective multi-centre cohort study

258P Real-world (rw) outcomes in patients (pts) with hormone receptor-positive and human epidermal growth factor receptor-2-negative (HR+/HER2-) metastatic breast cancer (mBC) treated with chemotherapy (CT) in France

To which extent do breast cancer survivors feel well informed about disease and treatment 5 years after diagnosis?

Endocrine therapy in obese patients with primary breast cancer: another piece of evidence in an unfinished puzzle

216P What is driving treatment decision following 1st line ribociclib (RIB) + aromatase inhibitor (AI)/fulvestrant (FUL) in clinical routine? Real-world data from the RIBANNA study (6th interim analysis (IA))

German National Consensus Recommendations on Nutrition and Lifestyle in Pregnancy by the ‘Healthy Start – Young Family Network’

Positive Effect of HPA Lanolin versus Expressed Breastmilk on Painful and Damaged Nipples during Lactation

A comparison of international breast cancer guidelines – Do the national guidelines differ in treatment recommendations?

Suchergebnisse filtern